1 / 32

中草藥研發新契機

中草藥研發新契機. 抗潰瘍及抗憂鬱中草藥研發案例分享. 柯 逢 年 博士. 財團法人製藥工業技術發展中心 二 OO 二年十月二十五日. 我國中草藥研發的優勢與契機. 1. 中草藥自成理論體系，非華人不易理解 2. 國外大廠目前尚未積極介入 3. 國內已有充分研發基礎與經驗 4. 充分了解 TCM 之特點，易與現代疾病關聯，掌握研 發契機 5. 研發技術較中國領先 6. 製造技術優良，品質管控亦較中國為佳 7. 國內由臨床前至臨床研發體系逐步建立並趨完善 8. 政府全力支持與投入. 國內外市場及發展趨勢 - I. 國內外市場及發展趨勢 - II.

manchu
Download Presentation

中草藥研發新契機

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 中草藥研發新契機 抗潰瘍及抗憂鬱中草藥研發案例分享 柯 逢 年 博士 財團法人製藥工業技術發展中心 二OO二年十月二十五日

  2. 我國中草藥研發的優勢與契機 1.中草藥自成理論體系，非華人不易理解 2.國外大廠目前尚未積極介入 3.國內已有充分研發基礎與經驗 4.充分了解TCM之特點，易與現代疾病關聯，掌握研 發契機 5.研發技術較中國領先 6.製造技術優良，品質管控亦較中國為佳 7.國內由臨床前至臨床研發體系逐步建立並趨完善 8.政府全力支持與投入

  3. 國內外市場及發展趨勢 - I

  4. 國內外市場及發展趨勢 - II 1.WHO Traditional Medicine Strategy 2002-2005, 2002/05. 2.WHO 2002/05 report. 3.中國中醫藥信息雜誌 2002年4月 4. ITIS 2001/12 report.

  5. 西藥(化學合成藥品)目前之困境 1.跨國大藥廠專利逐漸到期 2.花費5至8億美金，9至11年才能發展一新藥 3.R&D經費每五年增加一倍 4.New chemical leads雖增加(1995年5492個； 2000年8191個)，但新藥(new chemical entity)核准數並未增加

  6. R & D Costs of New Chemical Entity and Herbal Medicine * Waive：for products with sufficient human experience and scientific literatures Ref：GloboMax LLC Unit：Thousands of USD

  7. 法規面的配合（一）

  8. 法規面的配合（二）

  9. 對FDA草案的一般認知 ? ? ? 文獻記載 人體使用歷史 療效已獲驗證 安全性,毒性無虞 快速進入臨床實驗 縮短臨床實驗流程 產品上市 The preclinical pharmacology and toxicology information that should be provided for legally available botanical products with no known safety issues during initial clinical trials may be markedly reduced compared to that expected for synthetic ……and for which there is no prior human experience. (from Guidance for Industry Botanical Drug Products)

  10. The Amount of Information in an IND Submission Depends on : • The novelty of the drug • The extent to which it has been studied previously • The drug products known or suspected risks • The development phase of the drug • (from Guidance for Industry Botanical Drug Products)

  11. 中草藥研發的助力與阻力 Raw material的管控 CMC的技術難度 化學及療效一致性的驗證 安定性的證明 藥動學的研究 智財權的保護 傳統中草藥 新興中草藥 理論體系的差異 產品間的差異 嚴謹的臨床試驗 文獻資料 人體使用經驗及歷史 療效 安全性

  12. Disadvantages of Traditional Chinese Medicines • Far from modern sciences • Far from controllable • Poor standardization • Formulation types not accepted

  13. Research and Development of Herbal Medicine： a Way from Traditional Chinese Medicine Formulation to Extract of Single Herb 傳統複方 ↓活性導向 加、減方探討 ↓ 單一藥材 ↓活性導向，專利考量 替代藥材 ↓ ↓品管、配方、製程、活性、毒理 ↓ 產品

  14. Control of Raw Material —Ⅰ

  15. Control of Raw Material —II

  16. HPLC Chromatogram mAU Standard A Standard E 150 Standard C Standard D 100 50 0 0 10 20 30 40 min 150 100 50 0 20 30 40 min 0 10

  17. Specifications of Drug Substance 18

  18. Specification of Drug Product 19

  19. Stability Study — Chemical 21 篩選 KoFN 021025

  20. Target Primary pharmacodynamics Pharmacological Studies Safety Pharmacology Secondary pharmacodynamics

  21. Toxicology Studies 單劑量毒性試驗 重覆劑量毒性試驗 生殖毒性試驗 基因突變性試驗 ……

  22. Principles of the TCM Tranquilizers • Nourish the heart and tranquilize the mind • ( 養心安神 ) • Clear away heart-fire and tranquilize the mind • ( 清心火,定精安神 ) • Tranquilize the mind, enrich vital energy and blood • ( 養心安神,補血益氣 ) • Nourish the heart, benefit the liver and tranquilize the mind ( 養心益肝,寧心安神 ) • Tranquilize the mind and disperse the depressed vital • ( 安神解鬱 )

  23. Clinical Uses of the TCM Tranquilizers • Palpitation • Frightening • Irritability • Insomnia • Dreaminess • Amnesia

  24. 安神中草藥的現代研究  Sedative - Hypnotic (prolong barbiturate - induced sleeping time)  Locomotor activity  Anxiety  Memory

  25. Effects of Extract and Imipramine on TBZ-Induced Hypothermia

  26. HPLC分析-I

  27. HPLC分析-II

  28. Norepinephrine, Dopamine and Serotonin Uptake Assay - I

  29. Norepinephrine, Dopamine and Serotonin Uptake Assay - II

  30. Modernization Science-based Standardization 品 質 CMC 療 效 Pharmacology 安 全 性 Toxicology Technology Protection Value Information for Initial Clinical Studies Experience–based Chinese medical theory guided New Herbal Medicines Efficacy Safety Quality 32 篩選 KoFN 021025

More Related